⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14891731 | 0.84 | MEN1 (0.38) | — | |
| SCHEMBL14892638 | 0.82 | MEN1 (0.37) | — | |
| SCHEMBL14892794 | 0.80 | MEN1 (0.35) | — | |
| SCHEMBL426289 | 0.77 | — | — | |
| SCHEMBL17672729 | 0.76 | CA1 (0.36) | — | |
| SCHEMBL4886131 | 0.74 | — | — | |
| SCHEMBL1319818 | 0.74 | — | — | |
| SCHEMBL48410 | 0.74 | MEN1 (0.42) | — | |
| SCHEMBL23369218 | 0.72 | — | — | |
| SCHEMBL796093 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187450-B2 | Substituted pyridine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| EP-2592076-B1 | SUBSTITUTED PYRIDINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-05-13 | — | — | EP | disclosed |
| CN-103221405-B | Substituted pyridine compound | DAIICHI SANKYO CO LTD | 2015-04-22 | — | — | CN | disclosed |
| US-20140213549-A9 | Substituted Pyridine Compound | UBE INDUSTRIES, LTD. (JP) | 2014-07-31 | — | — | US | disclosed |
| US-20140005143-A2 | Substituted PyridineCompound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-01-02 | — | — | US | disclosed |
| CN-103221405-A | Substituted pyridine compound | DAIICHI SANKYO CO LTD | 2013-07-24 | — | — | CN | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| EP-2592076-A1 | SUBSTITUTED PYRIDINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109653-A1 | Substituted Pyridine Compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-7989460-B2 | potent kinase insert domain-containing receptor (KDR) inhibitors with improved selectivity and pharmacokinetics; VEGF (vascular endothelial growth factor) inhibitors; cancer and rheumatoid arthritis; e.g. 7-(2-[4-(acetylmethyl)piperazin-1-yl]ethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1311500-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| CN-1346271-A | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA UK LTD (SE) | 2002-04-24 | — | — | CN | disclosed |
| WO-2002016348-A1 | ANTIANGIOGENIC BICYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012227-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |